Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26742436 | 1.00 | CNR2 (0.39) | CNR2KDM4EASPHKDM8GCK | |
| SCHEMBL31003308 | 0.87 | CNR2 (0.41) | CNR2KDM4EASPHKDM8GCK | |
| SCHEMBL24510124 | 0.74 | PDE4A (0.40) | KDM4EASPHKDM8 | |
| SCHEMBL28115039 | 0.73 | TLR9 (0.42) | CYP17A1 | |
| SCHEMBL30937642 | 0.73 | ASPH (0.44) | KDM4EASPHKDM8 | |
| SCHEMBL29743774 | 0.72 | KDM4E (0.41) | KDM4EASPHKDM8 | |
| SCHEMBL24510117 | 0.72 | KDM4E (0.41) | KDM4EASPHKDM8 | |
| SCHEMBL24387261 | 0.72 | KDM4E (0.43) | KDM4EASPHKDM8 | |
| SCHEMBL22990318 | 0.70 | TSHR (0.46) | KDM4EASPHKDM8 | |
| SCHEMBL30525611 | 0.70 | TSHR (0.46) | KDM4EASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | FGFR2, FGFR1, FGFR3 | CNR2 1721/4885KDM4E 915/4885ASPH 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.